Febit has formed a scientific advisory board. The board will be chaired by Mark Chee, CEO of Prognosys Biosciences, a collaborator of Febit. Chee is a co-founder of Illumina and a former Affymetrix scientist.
The other members are Karoly Nikolich, an entrepreneur and consultant, and the former executive director of the Neuroscience Institute of Stanford; David Lockhart, CSO of Amicus Therapeutics and a former Affymetrix employee; Mostafa Ronaghi, a senior research associate at the Stanford University Genome Technology Center and an inventor of pyrosequencing; and Jeffrey Trent, president and scientific director of the Translational Genomics Research Institute.
Tracy Warren and Edward Erickson are joining the board of directors of BioNanomatrix, following the company’s recent $5.1 million Series A funding round (see Short Reads, in this issue). Warren is a general partner of Battelle Ventures, the lead investor in the round, and Erickson has “extensive experience” in the medical products industry, according to BioNanomatrix.